ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (70)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Paciocco, G.
Right arrow Articles by Rubenfire, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paciocco, G.
Right arrow Articles by Rubenfire, M.
Eur Respir J 2001; 17:647-652
Copyright ©ERS Journals Ltd 2001

Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension

G. Paciocco1, F.J. Martinez2, E. Bossone1, E. Pielsticker1, B. Gillespie3 and M. Rubenfire1

1 Dept of Internal Medicine, Division of Cardiology, 2 Division of Pulmonary and Critical Care Medicine and 3 Centre for Biostatistics, University of Michigan

CORRESPONDENCE: M. Rubenfire, University of Michigan, 24 Frank Lloyd Wright Drive, 48106, Ann Arbor, MI, USA. Fax: 01 7349987456

Keywords: mortality, oximetry, pulmonary hypertension

Received: January 12, 2000
Accepted October 26, 2000

There are no reliable predictors of mortality in primary pulmonary hypertension (PPH). This study assessed whether exercise oxygen desaturation and distance achieved during a six-minute walk are associated with mortality in moderately symptomatic patients with PPH.

Thirty-four patients with PPH underwent a pretreatment six-minute walk test, and an invasive haemodynamic assessment of pulmonary vasodilator reserve, to select the best treatment option (epoprostenol in 27 and nifedipine in 7). Median follow-up was 26 months (12 months for the nonsurvivors was 26%), and median survival, >46 months by Kaplan-Maier estimate.

The mean±sd distance walked was 275±155 m and reduction in arterial oxygen saturation (Sa,O2) at maximal distance ({Delta}Sa,O2) was 8.4±4.5%. A distance ≤300 m increased mortality risk by 2.4, and a {Delta}Sa,O2 of ≥10 % increased mortality risk by 2.9. Only Sa,O2 at peak distance, {Delta}Sa,O2 and pulmonary vascular resistance (PVR) were related to mortality. After adjusting for PVR, there remained a 27% increase in risk of death for each per cent decrease in Sa,O2.

The six-minute walk distance and exercise oxygen saturation may be helpful in selecting patients with primary pulmonary hypertension for whom transplant listing is appropriate.




This article has been cited by other articles:


Home page
 Eur Heart JHome page
Authors/Task Force Members, N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J.-L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, et al.
Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)
Eur. Heart J., October 2, 2009; 30(20): 2493 - 2537.
[Full Text] [PDF]

Home page
 ThoraxHome page
T J Corte, S J Wort, M A Gatzoulis, P Macdonald, D M Hansell, and A U Wells
Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension
Thorax, October 1, 2009; 64(10): 883 - 888.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. Rubenfire, G. Lippo, B. D. Bodini, F. Blasi, L. Allegra, and E. Bossone
Evaluating Health-Related Quality of Life, Work Ability, and Disability in Pulmonary Arterial Hypertension: An Unmet Need
Chest, August 1, 2009; 136(2): 597 - 603.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. J. Peacock, R. Naeije, N. Galie, and L. Rubin
End-points and clinical trial design in pulmonary arterial hypertension: have we made progress?
Eur. Respir. J., July 1, 2009; 34(1): 231 - 242.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. H. Salzman
The 6-Min Walk Test: Clinical and Research Role, Technique, Coding, and Reimbursement
Chest, May 1, 2009; 135(5): 1345 - 1352.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
C. P. Minniti, C. Sable, A. Campbell, S. Rana, G. Ensing, N. Dham, O. Onyekwere, M. Nouraie, G. J. Kato, M. T. Gladwin, et al.
Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation
Haematologica, March 1, 2009; 94(3): 340 - 347.
[Abstract] [Full Text] [PDF]

Home page
 The Journal of RheumatologyHome page
S. PAMIDI and S. MEHTA
Six-Minute Walk Test in Scleroderma-Associated Pulmonary Arterial Hypertension: Are We Counting What Counts?
J Rheumatol, February 1, 2009; 36(2): 216 - 218.
[Full Text] [PDF]

Home page
 The Journal of RheumatologyHome page
M. C. GARIN, K. B. HIGHLAND, R. M. SILVER, and C. STRANGE
Limitations to the 6-Minute Walk Test in Interstitial Lung Disease and Pulmonary Hypertension in Scleroderma
J Rheumatol, February 1, 2009; 36(2): 330 - 336.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
C. Casanova, C. Cote, J. M. Marin, V. Pinto-Plata, J. P. de Torres, A. Aguirre-Jaime, C. Vassaux, and B. R. Celli
Distance and Oxygen Desaturation During the 6-min Walk Test as Predictors of Long-term Mortality in Patients With COPD
Chest, October 1, 2008; 134(4): 746 - 752.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. J. Impens, S. Wangkaew, and J. R. Seibold
The 6-minute walk test in scleroderma--how measuring everything measures nothing
Rheumatology, October 1, 2008; 47(suppl_5): v68 - v69.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J. M. Bourbonnais and L. Samavati
Clinical predictors of pulmonary hypertension in sarcoidosis
Eur. Respir. J., August 1, 2008; 32(2): 296 - 302.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Lankeit, C. Dellas, A. Panzenbock, N. Skoro-Sajer, D. Bonderman, M. Olschewski, K. Schafer, M. Puls, S. Konstantinides, and I. M. Lang
Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension
Eur. Respir. J., May 1, 2008; 31(5): 1024 - 1029.
[Abstract] [Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
J. D. Edelman
Clinical Presentation, Differential Diagnosis, and Vasodilator Testing of Pulmonary Hypertension
Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2007; 11(2): 110 - 118.
[Abstract] [PDF]

Home page
 CirculationHome page
G.-P. Diller and M. A. Gatzoulis
Pulmonary Vascular Disease in Adults With Congenital Heart Disease
Circulation, February 27, 2007; 115(8): 1039 - 1050.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P. Palange, S. A. Ward, K-H. Carlsen, R. Casaburi, C. G. Gallagher, R. Gosselink, D. E. O'Donnell, L. Puente-Maestu, A. M. Schols, S. Singh, et al.
Recommendations on the use of exercise testing in clinical practice
Eur. Respir. J., January 1, 2007; 29(1): 185 - 209.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. Montani, R. Souza, C. Binkert, W. Fischli, G. Simonneau, M. Clozel, and M. Humbert
Endothelin-1/Endothelin-3 Ratio: A Potential Prognostic Factor of Pulmonary Arterial Hypertension
Chest, January 1, 2007; 131(1): 101 - 108.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
W. O. Villalba, P. D. Sampaio-Barros, M. C. Pereira, E. M. F. P. Cerqueira, C. A. Leme Jr, J. F. Marques-Neto, and I. A. Paschoal
Six-Minute Walk Test for the Evaluation of Pulmonary Disease Severity in Scleroderma Patients
Chest, January 1, 2007; 131(1): 217 - 222.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
S. Provencher, D. Chemla, P. Herve, O. Sitbon, M. Humbert, and G. Simonneau
Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension
Eur. Respir. J., January 1, 2006; 27(1): 114 - 120.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. C. White, N. Terrin, K. B. Miller, and H. F. Ryan
Impaired Respiratory and Skeletal Muscle Strength in Patients Prior to Hematopoietic Stem-Cell Transplantation
Chest, July 1, 2005; 128(1): 145 - 152.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
V. Jounieaux, D. Rose, and P. Aubry
Relationships between exercise-induced pulmonary hypertension and nocturnal desaturation
Eur. Respir. J., June 1, 2005; 25(6): 1126 - 1127.
[Full Text] [PDF]

Home page
 ChestHome page
E. Bossone, B. D. Bodini, A. Mazza, and L. Allegra
Pulmonary Arterial Hypertension: The Key Role of Echocardiography
Chest, May 1, 2005; 127(5): 1836 - 1843.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al.
Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology
Eur. Heart J., December 2, 2004; 25(24): 2243 - 2278.
[Full Text] [PDF]

Home page
 ChestHome page
M. McGoon, D. Gutterman, V. Steen, R. Barst, D. C. McCrory, T. A. Fortin, and J. E. Loyd
Screening, Early Detection, and Diagnosis of Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines
Chest, July 1, 2004; 126(1_suppl): 14S - 34S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
V. V. McLaughlin, K. W. Presberg, R. L. Doyle, S. H. Abman, D. C. McCrory, T. Fortin, and G. Ahearn
Prognosis of Pulmonary Arterial Hypertension*: ACCP Evidence-Based Clinical Practice Guidelines
Chest, July 1, 2004; 126(1_suppl): 78S - 92S.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. J. Barst, M. McGoon, A. Torbicki, O. Sitbon, M. J. Krowka, H. Olschewski, and S. Gaine
Diagnosis and differential assessment of pulmonary arterial hypertension
J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 40S - 47S.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. M. Hoeper, R. J. Oudiz, A. Peacock, V. F. Tapson, S. G. Haworth, A. E. Frost, and A. Torbicki
End points and clinical trial designs in pulmonary arterial hypertension: Clinical and regulatory perspectives
J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 48S - 55S.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
V. N. Lama, K. R. Flaherty, G. B. Toews, T. V. Colby, W. D. Travis, Q. Long, S. Murray, E. A. Kazerooni, B. H. Gross, J. P. Lynch III, et al.
Prognostic Value of Desaturation during a 6-Minute Walk Test in Idiopathic Interstitial Pneumonia
Am. J. Respir. Crit. Care Med., November 1, 2003; 168(9): 1084 - 1090.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
D. Chemla, V. Castelain, P. Herve, Y. Lecarpentier, and S. Brimioulle
Haemodynamic evaluation of pulmonary hypertension
Eur. Respir. J., November 1, 2002; 20(5): 1314 - 1331.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
X.-G. Sun, J. E. Hansen, R. J. Oudiz, and K. Wasserman
Gas Exchange Detection of Exercise-Induced Right-to-Left Shunt in Patients With Primary Pulmonary Hypertension
Circulation, January 1, 2002; 105(1): 54 - 60.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the European Respiratory Society.